Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation.

A retrospective analysis performed at our institution indicates that 30 % of the population develope atrial fibrillation in the postoperative period.

Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population.

Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after an initial loading bolus og 300 mg intravenously.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aarhus University Hospital
• Treatments: Amiodarone

Criteria

Inclusion Criteria:

• Resection of the lung due to confirmed diagnosis of cancer pulmones.

• Elective operation (scheduled operation for at least one day)

• Ready to be randomized

• Patient must be at least 18 at time of operation

Exclusion Criteria:

• Former operation of the lung

• Former heart surgery

• Bradycardia below 40 beats/ min

• Hypotension with systolic blood pressure below 80 mmHg

• AV-blockage of any degree or sick sinus node

• QTc interval above 440 ms for men or above 460 ms for women

• Paroxysmal, persistent or permanent atrial fibrillation or flutter

• Former atrial fibrillation or flutter for more than a month.

• Pregnant or positive pregnancy test

• Breastfeeding

• ALAT of more than twice the normal over limit

• Treatment with monoamineoxidase inhibitors (MAOI)

• Allergy to one or more components in amiodarone